Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes.
暂无分享,去创建一个
A. Sinha | A. Bagga | G. Ghiggeri | J. Hogan | C. Dossier | M. Kemper | M. Vivarelli | K. Tullus | Tomohiko Yamamura | K. Kamei | K. Ishikura | E. Yu | A. Ma | E. Chan | I. Liu | H. Webb | Priya Sharma